Investigating new treatments for diffuse large B-cell lymphoma
Project 4 Green-Davis
This study is looking for ways to improve treatment for patients with a specific type of lymphoma called activated B-cell diffuse large B-cell lymphoma (ABC DLBCL) by finding unique markers in their cancer that can help doctors choose the best therapies for them.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10847991 on NIH RePORTER |
What this research studies
This research focuses on diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, which is often treated with chemotherapy and the anti-CD20 antibody, Rituximab. The study aims to identify molecular biomarkers that can help tailor treatments specifically for patients with the activated B-cell (ABC) subtype of DLBCL, which has a poorer prognosis. By understanding the genetic and signaling pathways involved in this subtype, researchers hope to develop more effective therapies that target the underlying mechanisms of the disease. Patients may be involved in trials that explore new treatment options based on their specific cancer characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with diffuse large B-cell lymphoma, particularly those with the activated B-cell subtype.
Not a fit: Patients with other types of lymphoma or those who do not have diffuse large B-cell lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with diffuse large B-cell lymphoma.
How similar studies have performed: Previous research has shown promise in targeting specific molecular pathways in lymphoma, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Green, Michael Richard — Weill Medical Coll of Cornell Univ
- Study coordinator: Green, Michael Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.